Zobrazeno 1 - 5
of 5
pro vyhledávání: '"T. Yu. Kochetova"'
Autor:
V. V. Krylov, N. S. Legkodimova, T. Yu. Kochetova, V. M. Petriev, M. A. Sigov, V. K. Tishchenko, A. I. Pronin, A. Yu. Shurinov, K. M. Petrosyan, O. N. Spichenkova, O. B. Karyakin, V. A. Biryukov, V. F. Stepanenko, O. P. Vlasova, P. V. Shegaj, S. A. Ivanov, A. D. Kaprin
Publikováno v:
Diagnostic radiology and radiotherapy. 13:75-85
INTRODUCTION: The results of studies of clinical potential of a new domestic radiopharmaceutical 177Lu-DOTA-PSMA in patients with metastatic castration-resistant prostate cancer are presented in this article.OBJECTIVE: The pharmacokinetics, safety an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdb57b61a11e365eb7351e7acaa6c859
https://doi.org/10.22328/2079-5343-2022-13-4-75-85
https://doi.org/10.22328/2079-5343-2022-13-4-75-85
Autor:
V. V. Krylov, O.N. Korovchuk, T.I. Khvostunova, A. A. Rodichev, T. Yu. Kochetova, V.S. Pyatenko, A.S. Zhironkina, N.N. Shepel, I.K. Khvostunov
Publikováno v:
"Radiation and Risk" Bulletin of the National Radiation and Epidemiological Registry. 30:101-112
The radioiodine therapy is the most well-known branch of radionuclide therapy. The therapy composed of thyroidectomy and iodine-131 radiopharmaceutical is the “gold standard” for treat-ment of differentiated thyroid cancer patients (DTC). Given m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0dde12138e967e9a6bda52604fda102
https://doi.org/10.21870/0131-3878-2021-30-2-101-112
https://doi.org/10.21870/0131-3878-2021-30-2-101-112
Autor:
A. A. Rodichev, T. Yu. Kochetova, K. M. Petrosyan, V. V. Krylov, T. M. Geliashvili, E. V. Borodavina, P. I. Garbuzov, A. Yu. Shurinov
Publikováno v:
Diagnostic radiology and radiotherapy. 11:20-24
The latest recommendations of the American Thyroid Association have caused serious disagreements between the nuclear medicine and endocrinologist communities regarding the radioactive iodine use. In 2018 eighteen experts from 8 countries and 4 leadin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da3a8f456388c8c86aa1c7445e551853
https://doi.org/10.22328/2079-5343-2020-11-3-20-24
https://doi.org/10.22328/2079-5343-2020-11-3-20-24
Autor:
T Yu. Kochetova, V. V. Krylov, K. M. Petrosyan, O. B. Karyakin, V. A. Biryukov, B. Ya. Alekseev, V. B. Matveev, S. A. Ivanov, A. D. Kaprin
Publikováno v:
Onkourologiâ, Vol 16, Iss 1, Pp 114-123 (2020)
Radiopharmaceuticals previously used to treat patients with metastatic castrate-resistant prostate cancer and skeletal metastases were positioned as means to suppress pain, reduce analgesics consumption and improve the quality of life. They were usua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d251464b56b87861c8f7cb52a5acfd
https://doi.org/10.17650/1726-9776-2020-16-1-114-123
https://doi.org/10.17650/1726-9776-2020-16-1-114-123
Publikováno v:
Voprosy onkologii. 61(1)
Treatment of patients with multiple bone metastases accompanied by pain syndrome is a complicated clinical task. Radionuclide therapy is one of its solutions, which is used to achieve long reduction of pain syndrome and significant improvement the qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::80c20be7907bf132b42ee38a6f7c0a3f
https://pubmed.ncbi.nlm.nih.gov/26016139
https://pubmed.ncbi.nlm.nih.gov/26016139